Browsing Tag
ADC
10 posts
GlycoNex and Nippon Kayaku team up to advance next-generation ADC candidate GNX201-ADC in solid tumours
GlycoNex (4168) and Nippon Kayaku advance GNX201-ADC, a protease-activated ADC targeting solid tumours. Discover what this deal means for oncology. Read more.
Sai Life Sciences (NSE: SAILIFE) Q2 FY26 profit doubles on CRDMO demand, high-value tech expansion
Sai Life Sciences profit doubled in Q2 FY26, driven by peptide, ADC, and oligo expansion. See how the CRDMO firm is gaining margin and investor traction.
GSK’s B7-H3 ADC secures EU orphan drug status as it accelerates global lung cancer trials
GSK’s B7-H3-targeted ADC GSK’227 receives EU Orphan Drug Designation for small-cell lung cancer. Learn how it fits into the company’s expanding global trial program.
Kelun-Biotech reports strong Phase 3 data for sacituzumab tirumotecan in HR+/HER2- breast cancer
Kelun-Biotech’s sacituzumab tirumotecan doubled PFS in HR+/HER2- breast cancer. Find out what this means for patients, investors, and China’s ADC landscape.
NextCure brings Simcere Zaiming’s SIM0505 to U.S. trials as ADC race accelerates in oncology
Find out how NextCure and Simcere Zaiming are expanding SIM0505’s Phase 1 program into the U.S. and redefining the future of ADC collaboration.
Tempus joins forces with Whitehawk Therapeutics to power next-gen biomarker-based oncology trials
Find out how Tempus and Whitehawk are using AI and real-world data to transform biomarker-driven oncology—discover the collaboration’s science and market impact.
Is BioNTech finally breaking out of its COVID shadow? The case for its oncology comeback
Discover how BioNTech is transforming from COVID-19 pioneer to oncology powerhouse, led by ADC success and mRNA innovations. Read more now.
Can ifinatamab deruxtecan redefine treatment for late-stage small cell lung cancer? Here’s what the trial shows
Discover how ifinatamab deruxtecan delivered a 48% objective response rate in pretreated ES-SCLC. Read on for trial results and next steps.
BioNTech stock jumps 8.66% after DB-1303 meets primary endpoint in breast cancer trial
BioNTech stock surged after DB-1303 met its Phase 3 endpoint in HER2-positive breast cancer. Find out what this means for global oncology strategy.
GSK secures FDA breakthrough therapy designation for GSK5764227 in lung cancer treatment
GSK plc (LSE/NYSE: GSK) has announced a significant milestone in its oncology program, with the US Food and…